お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書はライソゾーム蓄積性疾患市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートはライソゾーム蓄積性疾患の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界のライソゾーム蓄積性疾患市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートはライソゾーム蓄積性疾患のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別にライソゾーム蓄積性疾患市場を分類しています。本研究に含まれる主な企業は：Actelion Pharmaceuticals、Amicus Therapeutics、Arena Pharmaceuticals、Astellas Pharma、Astrazeneca、Biomarin Pharmaceutical、Eli Lilly、Lexicon Pharmaceuticals、Novo Nordisk、Merck

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Lipid Metabolism Disorder
    Glycoprotein Metabolism Disorder

用途別の市場セグメント：
    Hospitals
    Clinics
    Others

本レポートの詳細内容
世界のライソゾーム蓄積性疾患市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、ライソゾーム蓄積性疾患タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業のライソゾーム蓄積性疾患収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界のライソゾーム蓄積性疾患市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、ライソゾーム蓄積性疾患市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

ライソゾーム蓄積性疾患のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：ライソゾーム蓄積性疾患のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：ライソゾーム蓄積性疾患の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章ライソゾーム蓄積性疾患企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：ライソゾーム蓄積性疾患の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：ライソゾーム蓄積性疾患の主要企業の概要を提供し、製品の説明と仕様、ライソゾーム蓄積性疾患の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

Lysosomal Storage Disease (LSD) is a genetic disorder that causes various types of nervous system disorders such as clinical abnormalities and cellular dysfunction. There are more than 65 categories of LSD. This disease can be classified into Lipid Metabolism Disorder and Glycoprotein Metabolism Disorder. Further Lipid Metabolism Disorder is categorized into Gaucher disease & Fabry disease and Glycoprotein Metabolism Disorder into Pompe disease. LSD develops mainly due to deficiency of lysosomal enzyme in the living body. A person suffering from LSD could experience problems like abnormal growth of bones, delay movement of body, deafness, blindness, dementia, respiratory problems, fatigue/weakness, bone & joint deformity, organ enlargement, lung dysfunction, severe & fatal physical & mental health deterioration.
Market Analysis and Insights: Global Lysosomal Storage Disease (LSD) Market
The global Lysosomal Storage Disease (LSD) market is projected to grow from US$ 7847.7 million in 2024 to US$ 10460 million by 2030, at a Compound Annual Growth Rate (CAGR) of 4.9% during the forecast period.
The global LSD market is expected to grow with growing Ashkenazi (Eastern and Western Europe) population, increasing pharmaceutical R&D spending, growing disposable income, rising healthcare expenditure and accelerating economic growth. Key trends of this rare disease market includes progressing drugs under pipeline and increasing preference towards gene therapy. However, there are some factors which can hinder growth of the market including stringent regulations and limited access to patent rights.
Report Covers:
This report presents an overview of global market for Lysosomal Storage Disease (LSD) market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Lysosomal Storage Disease (LSD), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Lysosomal Storage Disease (LSD), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Lysosomal Storage Disease (LSD) revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Lysosomal Storage Disease (LSD) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Lysosomal Storage Disease (LSD) revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Actelion Pharmaceuticals, Amicus Therapeutics, Arena Pharmaceuticals, Astellas Pharma, Astrazeneca, Biomarin Pharmaceutical, Eli Lilly, Lexicon Pharmaceuticals and Novo Nordisk, etc.

Market Segmentation
By Company
    Actelion Pharmaceuticals
    Amicus Therapeutics
    Arena Pharmaceuticals
    Astellas Pharma
    Astrazeneca
    Biomarin Pharmaceutical
    Eli Lilly
    Lexicon Pharmaceuticals
    Novo Nordisk
    Merck

Segment by Type
    Lipid Metabolism Disorder
    Glycoprotein Metabolism Disorder

Segment by Application
    Hospitals
    Clinics
    Others

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Lysosomal Storage Disease (LSD) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Lysosomal Storage Disease (LSD) companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Lysosomal Storage Disease (LSD) revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Lysosomal Storage Disease (LSD) Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Lipid Metabolism Disorder
    Table 3. Key Players of Glycoprotein Metabolism Disorder
    Table 4. Global Lysosomal Storage Disease (LSD) Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 5. Global Lysosomal Storage Disease (LSD) Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 6. Global Lysosomal Storage Disease (LSD) Market Size by Region (2019-2024) & (US$ Million)
    Table 7. Global Lysosomal Storage Disease (LSD) Market Share by Region (2019-2024)
    Table 8. Global Lysosomal Storage Disease (LSD) Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 9. Global Lysosomal Storage Disease (LSD) Market Share by Region (2025-2030)
    Table 10. Lysosomal Storage Disease (LSD) Market Trends
    Table 11. Lysosomal Storage Disease (LSD) Market Drivers
    Table 12. Lysosomal Storage Disease (LSD) Market Challenges
    Table 13. Lysosomal Storage Disease (LSD) Market Restraints
    Table 14. Global Lysosomal Storage Disease (LSD) Revenue by Players (2019-2024) & (US$ Million)
    Table 15. Global Lysosomal Storage Disease (LSD) Revenue Share by Players (2019-2024)
    Table 16. Global Top Lysosomal Storage Disease (LSD) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lysosomal Storage Disease (LSD) as of 2023)
    Table 17. Global Lysosomal Storage Disease (LSD) Industry Ranking 2022 VS 2023 VS 2024
    Table 18. Global 5 Largest Players Market Share by Lysosomal Storage Disease (LSD) Revenue (CR5 and HHI) & (2019-2024)
    Table 19. Global Key Players of Lysosomal Storage Disease (LSD), Headquarters and Area Served
    Table 20. Global Key Players of Lysosomal Storage Disease (LSD), Product and Application
    Table 21. Global Key Players of Lysosomal Storage Disease (LSD), Product and Application
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Lysosomal Storage Disease (LSD) Market Size by Type (2019-2024) & (US$ Million)
    Table 24. Global Lysosomal Storage Disease (LSD) Revenue Market Share by Type (2019-2024)
    Table 25. Global Lysosomal Storage Disease (LSD) Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 26. Global Lysosomal Storage Disease (LSD) Revenue Market Share by Type (2025-2030)
    Table 27. Global Lysosomal Storage Disease (LSD) Market Size by Application (2019-2024) & (US$ Million)
    Table 28. Global Lysosomal Storage Disease (LSD) Revenue Share by Application (2019-2024)
    Table 29. Global Lysosomal Storage Disease (LSD) Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 30. Global Lysosomal Storage Disease (LSD) Revenue Share by Application (2025-2030)
    Table 31. North America Lysosomal Storage Disease (LSD) Market Size by Type (2019-2024) & (US$ Million)
    Table 32. North America Lysosomal Storage Disease (LSD) Market Size by Type (2025-2030) & (US$ Million)
    Table 33. North America Lysosomal Storage Disease (LSD) Market Size by Application (2019-2024) & (US$ Million)
    Table 34. North America Lysosomal Storage Disease (LSD) Market Size by Application (2025-2030) & (US$ Million)
    Table 35. North America Lysosomal Storage Disease (LSD) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 36. North America Lysosomal Storage Disease (LSD) Market Size by Country (2019-2024) & (US$ Million)
    Table 37. North America Lysosomal Storage Disease (LSD) Market Size by Country (2025-2030) & (US$ Million)
    Table 38. Europe Lysosomal Storage Disease (LSD) Market Size by Type (2019-2024) & (US$ Million)
    Table 39. Europe Lysosomal Storage Disease (LSD) Market Size by Type (2025-2030) & (US$ Million)
    Table 40. Europe Lysosomal Storage Disease (LSD) Market Size by Application (2019-2024) & (US$ Million)
    Table 41. Europe Lysosomal Storage Disease (LSD) Market Size by Application (2025-2030) & (US$ Million)
    Table 42. Europe Lysosomal Storage Disease (LSD) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 43. Europe Lysosomal Storage Disease (LSD) Market Size by Country (2019-2024) & (US$ Million)
    Table 44. Europe Lysosomal Storage Disease (LSD) Market Size by Country (2025-2030) & (US$ Million)
    Table 45. China Lysosomal Storage Disease (LSD) Market Size by Type (2019-2024) & (US$ Million)
    Table 46. China Lysosomal Storage Disease (LSD) Market Size by Type (2025-2030) & (US$ Million)
    Table 47. China Lysosomal Storage Disease (LSD) Market Size by Application (2019-2024) & (US$ Million)
    Table 48. China Lysosomal Storage Disease (LSD) Market Size by Application (2025-2030) & (US$ Million)
    Table 49. Asia Lysosomal Storage Disease (LSD) Market Size by Type (2019-2024) & (US$ Million)
    Table 50. Asia Lysosomal Storage Disease (LSD) Market Size by Type (2025-2030) & (US$ Million)
    Table 51. Asia Lysosomal Storage Disease (LSD) Market Size by Application (2019-2024) & (US$ Million)
    Table 52. Asia Lysosomal Storage Disease (LSD) Market Size by Application (2025-2030) & (US$ Million)
    Table 53. Asia Lysosomal Storage Disease (LSD) Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 54. Asia Lysosomal Storage Disease (LSD) Market Size by Region (2019-2024) & (US$ Million)
    Table 55. Asia Lysosomal Storage Disease (LSD) Market Size by Region (2025-2030) & (US$ Million)
    Table 56. Middle East, Africa, and Latin America Lysosomal Storage Disease (LSD) Market Size by Type (2019-2024) & (US$ Million)
    Table 57. Middle East, Africa, and Latin America Lysosomal Storage Disease (LSD) Market Size by Type (2025-2030) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Lysosomal Storage Disease (LSD) Market Size by Application (2019-2024) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Lysosomal Storage Disease (LSD) Market Size by Application (2025-2030) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Lysosomal Storage Disease (LSD) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 61. Middle East, Africa, and Latin America Lysosomal Storage Disease (LSD) Market Size by Country (2019-2024) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Lysosomal Storage Disease (LSD) Market Size by Country (2025-2030) & (US$ Million)
    Table 63. Actelion Pharmaceuticals Company Details
    Table 64. Actelion Pharmaceuticals Business Overview
    Table 65. Actelion Pharmaceuticals Lysosomal Storage Disease (LSD) Product
    Table 66. Actelion Pharmaceuticals Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024) & (US$ Million)
    Table 67. Actelion Pharmaceuticals Recent Developments
    Table 68. Amicus Therapeutics Company Details
    Table 69. Amicus Therapeutics Business Overview
    Table 70. Amicus Therapeutics Lysosomal Storage Disease (LSD) Product
    Table 71. Amicus Therapeutics Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024) & (US$ Million)
    Table 72. Amicus Therapeutics Recent Developments
    Table 73. Arena Pharmaceuticals Company Details
    Table 74. Arena Pharmaceuticals Business Overview
    Table 75. Arena Pharmaceuticals Lysosomal Storage Disease (LSD) Product
    Table 76. Arena Pharmaceuticals Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024) & (US$ Million)
    Table 77. Arena Pharmaceuticals Recent Developments
    Table 78. Astellas Pharma Company Details
    Table 79. Astellas Pharma Business Overview
    Table 80. Astellas Pharma Lysosomal Storage Disease (LSD) Product
    Table 81. Astellas Pharma Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024) & (US$ Million)
    Table 82. Astellas Pharma Recent Developments
    Table 83. Astrazeneca Company Details
    Table 84. Astrazeneca Business Overview
    Table 85. Astrazeneca Lysosomal Storage Disease (LSD) Product
    Table 86. Astrazeneca Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024) & (US$ Million)
    Table 87. Astrazeneca Recent Developments
    Table 88. Biomarin Pharmaceutical Company Details
    Table 89. Biomarin Pharmaceutical Business Overview
    Table 90. Biomarin Pharmaceutical Lysosomal Storage Disease (LSD) Product
    Table 91. Biomarin Pharmaceutical Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024) & (US$ Million)
    Table 92. Biomarin Pharmaceutical Recent Developments
    Table 93. Eli Lilly Company Details
    Table 94. Eli Lilly Business Overview
    Table 95. Eli Lilly Lysosomal Storage Disease (LSD) Product
    Table 96. Eli Lilly Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024) & (US$ Million)
    Table 97. Eli Lilly Recent Developments
    Table 98. Lexicon Pharmaceuticals Company Details
    Table 99. Lexicon Pharmaceuticals Business Overview
    Table 100. Lexicon Pharmaceuticals Lysosomal Storage Disease (LSD) Product
    Table 101. Lexicon Pharmaceuticals Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024) & (US$ Million)
    Table 102. Lexicon Pharmaceuticals Recent Developments
    Table 103. Novo Nordisk Company Details
    Table 104. Novo Nordisk Business Overview
    Table 105. Novo Nordisk Lysosomal Storage Disease (LSD) Product
    Table 106. Novo Nordisk Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024) & (US$ Million)
    Table 107. Novo Nordisk Recent Developments
    Table 108. Merck Company Details
    Table 109. Merck Business Overview
    Table 110. Merck Lysosomal Storage Disease (LSD) Product
    Table 111. Merck Revenue in Lysosomal Storage Disease (LSD) Business (2019-2024) & (US$ Million)
    Table 112. Merck Recent Developments
    Table 113. Research Programs/Design for This Report
    Table 114. Key Data Information from Secondary Sources
    Table 115. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Lysosomal Storage Disease (LSD) Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Lysosomal Storage Disease (LSD) Market Share by Type: 2023 VS 2030
    Figure 3. Lipid Metabolism Disorder Features
    Figure 4. Glycoprotein Metabolism Disorder Features
    Figure 5. Global Lysosomal Storage Disease (LSD) Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 6. Global Lysosomal Storage Disease (LSD) Market Share by Application: 2023 VS 2030
    Figure 7. Hospitals Case Studies
    Figure 8. Clinics Case Studies
    Figure 9. Others Case Studies
    Figure 10. Lysosomal Storage Disease (LSD) Report Years Considered
    Figure 11. Global Lysosomal Storage Disease (LSD) Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 12. Global Lysosomal Storage Disease (LSD) Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 13. Global Lysosomal Storage Disease (LSD) Market Share by Region: 2023 VS 2030
    Figure 14. Global Lysosomal Storage Disease (LSD) Market Share by Players in 2023
    Figure 15. Global Top Lysosomal Storage Disease (LSD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lysosomal Storage Disease (LSD) as of 2023)
    Figure 16. The Top 10 and 5 Players Market Share by Lysosomal Storage Disease (LSD) Revenue in 2023
    Figure 17. North America Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 18. North America Lysosomal Storage Disease (LSD) Market Share by Type (2019-2030)
    Figure 19. North America Lysosomal Storage Disease (LSD) Market Share by Application (2019-2030)
    Figure 20. North America Lysosomal Storage Disease (LSD) Market Share by Country (2019-2030)
    Figure 21. United States Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. Canada Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Europe Lysosomal Storage Disease (LSD) Market Size YoY (2019-2030) & (US$ Million)
    Figure 24. Europe Lysosomal Storage Disease (LSD) Market Share by Type (2019-2030)
    Figure 25. Europe Lysosomal Storage Disease (LSD) Market Share by Application (2019-2030)
    Figure 26. Europe Lysosomal Storage Disease (LSD) Market Share by Country (2019-2030)
    Figure 27. Germany Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. France Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. U.K. Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Italy Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Russia Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Nordic Countries Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. China Lysosomal Storage Disease (LSD) Market Size YoY (2019-2030) & (US$ Million)
    Figure 34. China Lysosomal Storage Disease (LSD) Market Share by Type (2019-2030)
    Figure 35. China Lysosomal Storage Disease (LSD) Market Share by Application (2019-2030)
    Figure 36. Asia Lysosomal Storage Disease (LSD) Market Size YoY (2019-2030) & (US$ Million)
    Figure 37. Asia Lysosomal Storage Disease (LSD) Market Share by Type (2019-2030)
    Figure 38. Asia Lysosomal Storage Disease (LSD) Market Share by Application (2019-2030)
    Figure 39. Asia Lysosomal Storage Disease (LSD) Market Share by Region (2019-2030)
    Figure 40. Japan Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. South Korea Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. China Taiwan Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. Southeast Asia Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. India Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Australia Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Middle East, Africa, and Latin America Lysosomal Storage Disease (LSD) Market Size YoY (2019-2030) & (US$ Million)
    Figure 47. Middle East, Africa, and Latin America Lysosomal Storage Disease (LSD) Market Share by Type (2019-2030)
    Figure 48. Middle East, Africa, and Latin America Lysosomal Storage Disease (LSD) Market Share by Application (2019-2030)
    Figure 49. Middle East, Africa, and Latin America Lysosomal Storage Disease (LSD) Market Share by Country (2019-2030)
    Figure 50. Brazil Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 51. Mexico Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 52. Turkey Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Saudi Arabia Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Israel Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. GCC Countries Lysosomal Storage Disease (LSD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Actelion Pharmaceuticals Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2019-2024)
    Figure 57. Amicus Therapeutics Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2019-2024)
    Figure 58. Arena Pharmaceuticals Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2019-2024)
    Figure 59. Astellas Pharma Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2019-2024)
    Figure 60. Astrazeneca Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2019-2024)
    Figure 61. Biomarin Pharmaceutical Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2019-2024)
    Figure 62. Eli Lilly Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2019-2024)
    Figure 63. Lexicon Pharmaceuticals Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2019-2024)
    Figure 64. Novo Nordisk Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2019-2024)
    Figure 65. Merck Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2019-2024)
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed